shares of pfizer inc pfe gained 02 in premarket trading on monday after the company announced a deal with beam therapeutics inc beam worth up to 13 billion beams stock was up 49 before the market opened as part of the fouryear agreement the companies will use beams vivo base editing technology to develop drugs that treat rare genetic diseases of the liver muscle and central nervous system pfizer will pay beam 300 million upfront including milestone payments the deal could be worth up to 13 billion in addition to sales royalties for beam if any products are brought to market pfizers stock is down 56 so far this year while shares of beam have declined 117 the sp 500 spx is down 18